Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 4/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30161700 | 0.85 | GPR119 (0.42) | RXRARXRBRXRGATRKRAS | |
| SCHEMBL20699344 | 0.85 | GPR119 (0.42) | RXRARXRBRXRGATRKRAS | |
| SCHEMBL24304012 | 0.82 | RXRA (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL20711771 | 0.73 | GPR119 (0.43) | RXRARXRBRXRG | |
| SCHEMBL29607199 | 0.73 | GPR119 (0.43) | RXRARXRBRXRG | |
| SCHEMBL20699414 | 0.73 | RXRA (0.49) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30161540 | 0.73 | RXRA (0.49) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL20699398 | 0.71 | RXRA (0.41) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30161515 | 0.71 | RXRA (0.41) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL20699375 | 0.71 | TP53 (0.43) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | RXRA 3296/4885RXRB 3587/4885RXRG 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.